Eriksson et al., 20061010 Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. ODIXa-HIP Study Investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114(22):2374-81.
|
Intervention |
128 142 140 143 142 |
Rivaroxaban 5 mg Rivaroxaban 10 mg Rivaroxaban 20 mg Rivaroxaban 30 mg Rivaroxaban 40 mg |
7 days |
DVT 14.9%; major bleeding 2.3% DVT 10.6%; major bleeding 0.7% DVT 8.5%; major bleeding 4.3% DVT 13.5%; major bleeding 4.9% DVT 6.4%; major bleeding 5.1% Venous Doppler. No case of PE. Effective and safe in preventing PE/DVT. |
Eriksson et al., 20081111 Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-75.
|
Intervention |
2209 |
Rivaroxaban 10 mg |
35 days |
Major bleeding: 6 (0.3%) cases. Minor bleeding: 128 (2.1%) cases. PE: 4 (0.3%) cases. Deep venous thromboembolism: 4 (0.2%) DVT: 12 (0.8%) cases. Low incidence of thrombosis and safe to use in thromboprophylaxis. |
Kanan et al., 20081212 Kanan PS, Schwartsmann CR, Boschin LC, Conrad S, Silva MF. Estudo comparative entre rivaroxaban e enoxaparina na profilaxia de tromboembolismo venoso profundo em pacientes submetidos à artroplastia total do quadril. Rev Bras Ortop. 2008;43(8):319-28.
|
Intervention |
33 |
Rivaroxaban 10 mg |
32–36 days |
3 cases of DVT (phlebography 32–36 PO). No cases of PE or major bleeding. Effective. |
Anderson et al., 20131313 Anderson DR, Dunbar MJ, Bohm ER, Belzile E, Kahn SR, Zukor D, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med. 2013;158(11):800-6.
|
Intervention |
380 |
Aspirin® 81 mg |
28 days |
Proximal DVT 1 (0.3%) case. Major bleeding: 8 (2.1%) cases. No cases of PE. No cases of major bleeding. Effective and safe in prolonged thromboprophylaxis after THA. |
Ozler et al., 20151414 Özler T, Uluçay Ç, Önal A, Altıntaş F. Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. Acta Orthop Traumatol Turc. 2015;49(3):255-9.
|
Intervention |
60 60 |
Rivaroxaban 10 mg Dabigatran 220 mg |
30 days 30 days |
Minor bleeding: 3 patients (5%). Major bleeding: 1 patient (1.6%); minor bleeding: 2 patients (3.3%). Absence of DVT (Doppler). |
Clave et al., 20121515 Clavé A, Fazilleau F, Dumser D, Lacroix J. Efficacy of tranexamic acid on blood loss after primary cementless total hip replacement with rivaroxaban thromboprophylaxis: a case-control study in 70 patients. Orthop Traumatol Surg Res. 2012;98(5):484-90.
|
Observational |
70 |
Rivaroxaban 10 mg |
30 days |
Absence of thromboembolic complications (at hospital discharge and 3 months after). 4 patients transfused. |
Jobski et al., 20141616 Jobski K, Enders D, Amann U, Suzart K, Wallander MA, Schink T, et al. Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital. Eur J Clin Pharmacol. 2014;70(8):975-81.
|
Observational |
206 |
Rivaroxaban 10 mg |
35 days |
TEV 1%. |
Turpie et al., 20141717 Turpie AG, Haas S, Kreutz R, Mantovani LG, Pattanayak CW, Holberg G, et al. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. Thromb Haemost. 2014;111(1):94-102.
|
Observational |
8778 |
Rivaroxaban 10 mg |
33 days |
Thromboembolic events: 0.89%. Major bleeding: 0.4%. Effective and safe in preventing PE/DVT. |
Cossetto et al., 20121818 Cossetto DJ, Goudar A, Parkinson K. Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. J Orthop Surg (Hong Kong). 2012;20(3):341-3.
|
Observational |
50 |
Aspirin® 100 mg |
42 days |
DVT: 3 patients (USG - 5 PO). No cases of PE. |
Vulcano et al., 20121919 Vulcano E, Gesell M, Esposito A, Ma Y, Memtsoudis SG, Gonzalez Della Valle A. Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. Int Orthop. 2012;36(10):1995-2002.
|
Observational |
887 |
Aspirin® 325 mg (2×/daily) |
45 days |
Thromboembolic events: 18.8 (1.2%), PE: 5.6 (0.36%), pDVT: 7.0 (0.45%), dDVT: 5.6 (0.36%). Major bleeding: 5 (0.3%). |
Bonarelli et al., 20152020 Bonarelli S, Bacchin MR, Frugiuele I, Feoli MA, Facchini F, Altimari V. Dabigatran etexilate and LMWH for the prevention of venous thromboembolism in 532 patients undergoing hip surgery. Eur Rev Med Pharmacol Sci. 2015;19(5):897-903.
|
Observational |
211 |
Dabigatran 220 mg |
35 days |
Absence of symptomatic DVT or EP. |